{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:34:29Z","timestamp":1784097269842,"version":"3.55.0"},"reference-count":53,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>The vitals of Parkinson\u2019s disease (PD) address the often-ignored symptoms, which are considered either peripheral to the central core of motor symptoms of PD or secondary symptoms, which, nevertheless, have a key role in the quality of life (QoL) and wellness of people with Parkinson\u2019s (PwP) [...]<\/jats:p>","DOI":"10.3390\/jpm12121994","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T02:18:06Z","timestamp":1669947486000},"page":"1994","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Dashboard Vitals of Parkinson\u2019s: Not to Be Missed Yet an Unmet Need"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-0505","authenticated-orcid":false,"given":"Kallol Ray","family":"Chaudhuri","sequence":"first","affiliation":[{"name":"Institute of Psychiatry, Psychology & Neuroscience, Department of Basic & Clinical Neuroscience, Division of Neuroscience, King\u2019s College London, London SE5 9RT, UK"},{"name":"Parkinson Foundation Centre of Excellence in Care and Research, King\u2019s College Hospital NHS Foundation Trust, London SE5 9RS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Titova","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neurosurgery and Medical Genetics, Federal State Autonomous Educational Institution of Higher Education, N.I. Pirogov Russian National Research Medical University, The Ministry of Health of the Russian Federation, 117997 Moscow, Russia"},{"name":"Department of Neurodegenerative Diseases, Federal State Budgetary Institution, Federal Center of Brain Research and Neurotechnologies, The Federal Medical Biological Agency, 117997 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4105-5097","authenticated-orcid":false,"given":"Mubasher A.","family":"Qamar","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology & Neuroscience, Department of Basic & Clinical Neuroscience, Division of Neuroscience, King\u2019s College London, London SE5 9RT, UK"},{"name":"Parkinson Foundation Centre of Excellence in Care and Research, King\u2019s College Hospital NHS Foundation Trust, London SE5 9RS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia","family":"Mur\u0103\u0219an","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Transilvania University of Bra\u015fov, 500036 Bra\u0219ov, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Falup-Pecurariu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Transilvania University of Bra\u015fov, 500036 Bra\u0219ov, Romania"},{"name":"Department of Neurology, County Clinic Hospital, 500365 Bra\u0219ov, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/bs.irn.2021.12.006","article-title":"Wellness, sexual health, and nonmotor Parkinson\u2019s","volume":"162","author":"Subramanian","year":"2022","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.parkreldis.2020.09.024","article-title":"Unmet needs in Parkinson disease: Motor and non-motor","volume":"80","author":"LeWitt","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/bs.irn.2017.05.015","article-title":"Personalized Medicine and Nonmotor Symptoms in Parkinson\u2019s Disease","volume":"134","author":"Titova","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/mds.27027","article-title":"Personalized medicine in Parkinson\u2019s disease: Time to be precise","volume":"32","author":"Titova","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: Onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jclinepi.2004.09.014","article-title":"The SCOPA-Motor Scale for assessment of Parkinson\u2019s disease is a consistent and valid measure","volume":"58","author":"Burguera","year":"2005","journal-title":"J. Clin. Epidemiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/mds.10473","article-title":"The Unified Parkinson\u2019s Disease Rating Scale (UPDRS): Status and recommendations","volume":"18","author":"Disease","year":"2003","journal-title":"Mov. Disord."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3389\/fneur.2019.01027","article-title":"PKG Movement Recording System Use Shows Promise in Routine Clinical Care of Patients With Parkinson\u2019s Disease","volume":"10","author":"Joshi","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40734-020-00087-6","article-title":"Objective measurement in Parkinson\u2019s disease: A descriptive analysis of Parkinson\u2019s symptom scores from a large population of patients across the world using the Personal KinetiGraph\u00ae","volume":"7","author":"Pahwa","year":"2020","journal-title":"J. Clin. Mov. Disord."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.parkreldis.2011.08.013","article-title":"Validation of the non-motor symptoms questionnaire (NMS-Quest)","volume":"18","author":"Romenets","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/14737175.2018.1400383","article-title":"Comprehensive grading of Parkinson\u2019s disease using motor and non-motor assessments: Addressing a key unmet need","volume":"18","year":"2018","journal-title":"Expert Rev. Neurother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7861\/clinmedicine.16-4-365","article-title":"New concepts in the pathogenesis and presentation of Parkinson\u2019s disease","volume":"16","author":"Sauerbier","year":"2016","journal-title":"Clin. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.parkreldis.2014.12.031","article-title":"The burden of non-motor symptoms in Parkinson\u2019s disease using a self-completed non-motor questionnaire: A simple grading system","volume":"21","author":"Chaudhuri","year":"2015","journal-title":"Park. Relat. Disord."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/mdc3.12081","article-title":"How Do I Examine Nonmotor Aspects of Parkinson\u2019s Disease? What Not to Miss and What to Ignore?","volume":"1","author":"Todorova","year":"2014","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.parkreldis.2017.02.014","article-title":"Ocular and visual disorders in Parkinson\u2019s disease: Common but frequently overlooked","volume":"40","author":"Ekker","year":"2017","journal-title":"Park. Relat. Disord."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/bs.irn.2017.04.007","article-title":"Visual Dysfunction in Parkinson\u2019s Disease","volume":"134","author":"Armstrong","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3233\/JPD-150686","article-title":"Oculo-Visual Dysfunction in Parkinson\u2019s Disease","volume":"5","author":"Armstrong","year":"2015","journal-title":"J. Parkinsons. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Borm, C., Werkmann, M., Visser, F., Peball, M., Putz, D., Seppi, K., Poewe, W., Notting, I.C., Vlaar, A., and Theelen, T. (2019). Towards seeing the visual impairments in Parkinson\u2019s disease: Protocol for a multicentre observational, cross-sectional study. BMC Neurol., 19.","DOI":"10.1186\/s12883-019-1365-8"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1093\/brain\/awp223","article-title":"Impaired visual processing preceding image recognition in Parkinson\u2019s disease patients with visual hallucinations","volume":"132","author":"Meppelink","year":"2009","journal-title":"Brain"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.baga.2013.05.002","article-title":"Parkinson\u2019s disease and vision","volume":"3","author":"Sauerbier","year":"2013","journal-title":"Basal Ganglia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bone.2012.02.639","article-title":"Effect of co-morbidities on fracture risk: Findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW)","volume":"50","author":"Dennison","year":"2012","journal-title":"Bone"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00296-008-0632-6","article-title":"Prevalence and risk factors of osteoporosis in patients with Parkinson\u2019s disease","volume":"28","author":"Bezza","year":"2008","journal-title":"Rheumatol. Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/ageing\/afp137","article-title":"Bone and mineral metabolism in older adults with Parkinson\u2019s disease","volume":"38","author":"Helmii","year":"2009","journal-title":"Age Ageing"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/mds.20643","article-title":"Osteoporosis in Parkinson\u2019s disease","volume":"20","author":"Wood","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7754\/Clin.Lab.2019.190615","article-title":"The Relationship Among Bone Mineral Density, Bone Biomarkers and Vitamin D Levels in Patients with Parkinson\u2019s Disease","volume":"66","author":"Can","year":"2020","journal-title":"Clin. Lab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/bs.irn.2017.04.011","article-title":"Weight in Parkinson\u2019s Disease: Phenotypical Significance","volume":"134","author":"Sharma","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2217\/nmt.14.25","article-title":"Prognostic significance of weight changes in Parkinson\u2019s disease: The Park-weight phenotype","volume":"4","author":"Sharma","year":"2014","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1600-0404.2004.00307.x","article-title":"Factors of importance for weight loss in elderly patients with Parkinson\u2019s disease","volume":"110","author":"Ganowiak","year":"2004","journal-title":"Acta Neurol. Scand."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41531-022-00362-3","article-title":"Clinical trajectories and biomarkers for weight variability in early Parkinson\u2019s disease","volume":"8","author":"Urso","year":"2022","journal-title":"NPJ Parkinsons Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.parkreldis.2022.05.004","article-title":"Frailty in Parkinson\u2019s disease and its association with early dementia: A longitudinal study","volume":"99","author":"Borda","year":"2022","journal-title":"Park. Relat. Disord."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00415-021-10567-w","article-title":"Gastrointestinal dysfunction in Parkinson\u2019s disease: Molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation","volume":"269","author":"Metta","year":"2022","journal-title":"J. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3233\/JPD-212605","article-title":"Oral Health Disorders in Parkinson\u2019s Disease: More than Meets the Eye","volume":"11","author":"Auffret","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41531-022-00302-1","article-title":"Self-reported periodontitis and C-reactive protein in Parkinson\u2019s disease: A cross-sectional study of two American cohorts","volume":"8","author":"Lyra","year":"2022","journal-title":"NPJ Parkinsons Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3988\/jcn.2016.12.2.147","article-title":"Association between Parkinson\u2019s Disease and Helicobacter Pylori","volume":"12","year":"2016","journal-title":"J. Clin. Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.parkreldis.2014.12.009","article-title":"Helicobacter pylori infection is associated with worse severity of Parkinson\u2019s disease","volume":"21","author":"Tan","year":"2015","journal-title":"Park. Relat. Disord."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3233\/JPD-202298","article-title":"Effects of Helicobacter pylori on Levodopa Pharmacokinetics","volume":"11","author":"Nyholm","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3389\/fneur.2019.00621","article-title":"Severe Constipation in Parkinson\u2019s Disease and in Parkinsonisms: Prevalence and Affecting Factors","volume":"10","author":"Frazzitta","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"van Kessel, S.P., de Jong, H.R., Winkel, S.L., van Leeuwen, S.S., Nelemans, S.A., Permentier, H., Keshavarzian, A., and El Aidy, S. (2020). Gut bacterial deamination of residual levodopa medication for Parkinson\u2019s disease. BMC Biol., 18.","DOI":"10.1186\/s12915-020-00876-3"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/mds.28551","article-title":"Type 2 Diabetes as a Determinant of Parkinson\u2019s Disease Risk and Progression","volume":"36","author":"Chohan","year":"2021","journal-title":"Mov. Disord."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/brain\/awaa262","article-title":"Diabetes medications and risk of Parkinson\u2019s disease: A cohort study of patients with diabetes","volume":"143","author":"Brauer","year":"2020","journal-title":"Brain"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2337\/dc10-1922","article-title":"Diabetes and risk of Parkinson\u2019s disease","volume":"34","author":"Xu","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3389\/fneur.2020.00556","article-title":"Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson\u2019s Disease-Viewpoint","volume":"11","author":"Sportelli","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.2337\/dc11-1584","article-title":"Diabetes and risk of Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"34","author":"Cereda","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1212\/WNL.0000000000001364","article-title":"Parkinson risk in idiopathic REM sleep behavior disorder: Preparing for neuroprotective trials","volume":"84","author":"Postuma","year":"2015","journal-title":"Neurology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.sleep.2013.02.016","article-title":"Rapid eye movement sleep behavior disorder: Devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group","volume":"14","author":"Schenck","year":"2013","journal-title":"Sleep Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40035-016-0058-0","article-title":"Meta-analysis of risk factors for Parkinson\u2019s disease dementia","volume":"5","author":"Xu","year":"2016","journal-title":"Transl. Neurodegener."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/jnnp-2012-302684","article-title":"Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic","volume":"84","author":"Pondal","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40266-013-0090-z","article-title":"Dopamine agonist withdrawal syndrome: Implications for patient care","volume":"30","author":"Nirenberg","year":"2013","journal-title":"Drugs Aging"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/bs.irn.2017.04.006","article-title":"Impulse Control and Related Disorders in Parkinson\u2019s Disease","volume":"133","author":"Weintraub","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/14740338.2016.1130128","article-title":"A review of adverse events linked to dopamine agonists in the treatment of Parkinson\u2019s disease","volume":"15","author":"Ceravolo","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/nmt-2018-0020","article-title":"Noninvasive options for \u2018wearing-off\u2019 in Parkinson\u2019s disease: A clinical consensus from a panel of UK Parkinson\u2019s disease specialists","volume":"8","author":"Fackrell","year":"2018","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4103\/0974-2700.161658","article-title":"Comorbidity polypharmacy score and its clinical utility: A pragmatic practitioner\u2019s perspective","volume":"8","author":"Stawicki","year":"2015","journal-title":"J. Emerg. Trauma Shock"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/12\/1994\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:32:28Z","timestamp":1760146348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/12\/1994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":53,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["jpm12121994"],"URL":"https:\/\/doi.org\/10.3390\/jpm12121994","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]}}}